Apolipoprotein AIV as an antidiabetic peptide
US9266941B2 · kind B2 · utility
2Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 2015 |
| Grant date | Feb 23, 2016 |
| Priority date | — |
| Expiry date | May 5, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/6555
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type two diabetes mellitus. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.